- at -
Presented by: Glen P. Aylward, Ph.D., ABPP
A primary purpose of the Bayley-4 is to identify infants and toddlers who have delays in development. One way to verify the validity of the new test for this purpose is to compare children from at-risk groups to matched controls to determine if there are differences in scores. Infants and toddlers from specifically defined risk groups were included in the Bayley-4 validity studies (for example: children with Autism Spectrum Disorder; Language Delay; Developmental Delay; Motor Impairment; Prenatal Drug/Alcohol Exposure; Moderately or Late Preterm (32-36 weeks); and Extremely or Very Preterm (<32 weeks)). Children from these risk groups were compared on all the Bayley-4 subscales.
Based on the content of the webinar, participants will be able to:
-Describe the rationale for the inclusion of the clinical validity studies in Bayley-4.
-List at least three clinical groups included in the clinical validity studies for Bayley-4.
-Explain specific areas of function that are delayed and intervention strategies appropriate for at least three of the clinical groups described in the Bayley-4 validity studies.
Time-ordered Agenda (EDT):
11:00 to 11:10 AM
The rationale for clinical validity studies completed as part of the development of Bayley-4
11:10 to 11:50 AM
Comparison of clinical groups with matched control groups using Bayley-4. Including: Down Syndrome, Autism Spectrum Disorder, Language Delay, Specific Language Impairment, Developmental Delay, Motor Impairment, Prenatal Drug/Alcohol Exposure, Extremely or Very Preterm.
11:50 AM to 12:00 PM
Question & Answer Session